Neuroendocrine Tumor Clinical Trials

• Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.

• aged 18-75 years (including borderline values) at the time of signing the informed consent form

• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\

• The expected survival time is at least 12 weeks.

• According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion.

• Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.